These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16598303)

  • 1. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.
    Kiladjian JJ; Elkassar N; Cassinat B; Hetet G; Giraudier S; Balitrand N; Conejero C; Briere J; Fenaux P; Chomienne C; Grandchamp B
    Leukemia; 2006 Jun; 20(6):1181-3. PubMed ID: 16598303
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.
    Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM
    Leukemia; 2005 Oct; 19(10):1847-9. PubMed ID: 16079890
    [No Abstract]   [Full Text] [Related]  

  • 3. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
    Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.
    Cheung B; Radia D; Pantelidis P; Yadegarfar G; Harrison C
    Br J Haematol; 2006 Jan; 132(2):244-5. PubMed ID: 16398659
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients.
    Florensa L; Bellosillo B; Besses C; Puigdecanet E; Espinet B; Pérez-Vila E; Longarón R; Vilà RM; Solé F; Serrano S
    Leukemia; 2006 Oct; 20(10):1903-5. PubMed ID: 16888614
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
    Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
    Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
    Henry L; Carillo S; Jourdan E; Arnaud A; Brun S; Lavabre-Bertrand T
    Am J Hematol; 2007 Jun; 82(6):500-1. PubMed ID: 17301972
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis and management of essential thrombocythemia.
    Beer PA; Green AR
    Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
    Kronenwett R; Gräf T; Neumann F; Pechtel S; Steidl U; Diaz-Blanco E; Haas R
    Leuk Res; 2006 Oct; 30(10):1323-4. PubMed ID: 16442619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
    Tsantes AE; Nikolopoulos GK; Tsirigotis P; Zoi K; Zomas A; Kapsimali V; Kopterides P; Chondropoulos S; Dervenoulas J; Mantzios G
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):457-62. PubMed ID: 21836466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
    Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
    Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
    Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential thrombocythemia: scientific advances and current practice.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.